QRG Capital Management Inc. Has $18.42 Million Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• QRG Capital Management increased its Thermo Fisher Scientific stake by 48.6% in the second quarter, bringing its holdings to 36,743 shares valued at approximately $18.42 million. Institutional investors and hedge funds collectively own 89.23% of TMO.
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 in earnings per share and $11.99 billion in revenue, with revenue up 10.5% year over year. The company maintained fiscal 2026 EPS guidance of $24.93–$25.33.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $624.64, while TMO recently traded near its 12-month high at $665.77. The company also declared a quarterly dividend of $0.47 per share.

QRG Capital Management Inc. grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 48.6% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 36,743 shares of the medical research company's stock after buying an additional 12,014 shares during the period. QRG Capital Management Inc.'s holdings in Thermo Fisher Scientific were worth $18,422,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in TMO. BlackRock Inc. bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at $15,501,867,000. State Street Corp boosted its holdings in shares of Thermo Fisher Scientific by 1.4% in the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company's stock valued at $9,633,991,000 after buying an additional 229,630 shares during the period. Corient Private Wealth LP bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth $382,547,000. Capital World Investors lifted its position in Thermo Fisher Scientific by 7.0% in the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company's stock valued at $6,376,229,000 after acquiring an additional 718,669 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Thermo Fisher Scientific by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company's stock worth $4,728,129,000 after purchasing an additional 26,425 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Marc Casper sold 275 shares of Thermo Fisher Scientific stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $77,707,171.25. This trade represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph Holmes sold 420 shares of the business's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 73,768 shares of company stock valued at $44,122,820. Company insiders own 0.33% of the company's stock.

Wall Street Analyst Weigh In

TMO has been the topic of a number of research reports. Evercore set a $570.00 price target on Thermo Fisher Scientific in a report on Monday, July 6th. Jefferies Financial Group reissued a "buy" rating and issued a $630.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Royal Bank Of Canada upped their price target on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a "sector perform" rating in a research report on Friday, July 24th. Piper Sandler started coverage on shares of Thermo Fisher Scientific in a report on Wednesday, September 9th. They issued an "overweight" rating on the stock. Finally, Scotiabank began coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, September 9th. They set an "outperform" rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $624.64.

Key Stories Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher is identified as a key participant in the gene-transfer technologies market, which is projected to expand through 2036 as gene and cell therapies, genomic medicine investment, and vector-engineering technologies advance. This supports potential long-term demand for the company’s instruments, reagents, and manufacturing solutions. Gene Transfer Technologies Market report
• Positive Sentiment: The global bioreactors market is forecast to grow substantially through 2035, driven by single-use systems, automation, and advanced therapies. Thermo Fisher’s inclusion among the leading companies reinforces its exposure to expanding biomanufacturing demand. Bioreactors Market Outlook report
• Positive Sentiment: Thermo Fisher is participating in Precure LLC’s Mayo Clinic-led initiative to generate a one-million-sample multi-omic biomedical dataset. The project could increase visibility for Thermo Fisher’s sequencing, analysis, and research technologies while supporting future AI-driven precision medicine. Precure multi-omic dataset announcement
• Neutral Sentiment: Additional market reports highlight growth opportunities in ADME-toxicology testing, high-content screening, drug-discovery informatics, and automated closed cell-therapy processing—markets in which Thermo Fisher competes. These reports are industry outlooks rather than new contracts or financial guidance. ADME-Toxicology Testing report High Content Screening report Drug Discovery Informatics report
• Negative Sentiment: A market update indicated that TMO was lower ahead of the latest session, suggesting some near-term profit-taking or market caution after its strong recent advance. The report did not identify a new negative company development. Thermo Fisher premarket update

Thermo Fisher Scientific Trading Up 1.1%

Shares of Thermo Fisher Scientific stock opened at $665.77 on Thursday. The stock has a market cap of $246.17 billion, a P/E ratio of 35.81, a P/E/G ratio of 2.75 and a beta of 0.85. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $671.47. The business's 50 day moving average is $600.50 and its 200-day moving average is $526.15.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the previous year, the company earned $4.28 earnings per share. The firm's revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.